Effect of Deferiprone versus Deferiprone with Deferasirox in Iron Chelation Therapy of Thalassemia Children
Journal Title: Journal of Medical Science And clinical Research - Year 2018, Vol 6, Issue 9
Abstract
Background: Thalassemia is an autosomal recessive hemoglobin disorder requiring life-long blood transfusion causing iron overload. Combination therapy of oral iron chelators: Deferiprone (DFP) with Deferasirox (DFX) is an efficacious and safe modality to reduce serum ferritin in multi-transfused thalassemic children. This study was carried out to evaluate the effect of Deferiprone versus Deferiprone with Deferasirox in iron chelation therapy of transfusion dependent thalassemia children. Methodology: A cross sectional observational study was done in Pediatric Hematology and Oncology, Dhaka Medical College Hospital and Bangladesh Thalassemia Hospital in Dhaka from January to June 2018. Children with transfusion dependent β-thalassemia major and E-β-thalassemia having serum ferritin level >1000 ng/ml between 3 to 12 years of age were studied. Results: Demographic profile of 60 cases demonstrated that there are no significant differences in age, sex and weight between DFP-monotherapy and DFP-DFX-combination groups. Initial mean serum ferritin level was 3397.48±774.48 ng/ml in DFP-monotherapy group and 3413.70±1114.05ng/ml in DFP-DFX combination group. After treatment mean serum ferritin level at 6th month was 2730.63±839.91 ng/ml in DFP-monotherapy group and 1654.20±934.90 ng/ml in DFP-DFX-combination group which shows rapid reduction of serum ferritin level in DFP-DFX-combination group. Mean dose of drugs was 72.59(±3.76) mg/kg/ day of DFP in monotherapy group and 68.68(±4.84) mg/kg/ day of DFP and 27.98(±2.13) mg/kg/ day of DFX in combination group. 12 (40.0%) patients had arthralgia in DFP-monotherapy group and 5(16.7%) patients had vomiting in DFP-DFX-combination group. No abnormalities seen in liver and renal function tests. Conclusion: Deferiprone alone is capable in significant excretion of iron from the body in transfusion dependent thalassemia major patients. But combination therapy with Deferiprone and Deferasirox is more significantly effective in iron chelation and drug induced related complications.
Authors and Affiliations
Syeda Jarka Jahir
Keywords
Related Articles
- EP ID EP514962
- DOI -
- Views 81
- Downloads 0
A Rare Case of Hypokalemia Associated Central Pontine Myelinolysis: A Case Report
Central pontine myelinolysis (CPM) is a rare disorder characterized by non-inflammatory demyelination in the central pons. It was first reported in necropsy cases of alcoholism and malnutrition. It is a condition most fr...
Rapid Diagnosis of Toxigenic Clostridium difficile in eld erly patients in Tertiary setup
Background: Antibiotics cause diarrhoea due to infection by antibiotic resistant pathogens such as Staphylococcus aureus , Clostridium difficile, Candida albicans , Salmonella, C.perfringens...
Hemodynamic Stress Response during Laparoscopic Cholecystectomy: Effect of Oral Administration of Moxonidine
Background: In the event of laparoscopic surgeries, pneumoperitoneum can prelude to wide array of pathophysiologic changes in the cardiovascular system which may overture to hypertension and tachycardia. Thus, search for...
Clinical profile of diabetic patients with heart failure admitted in tertiary care teaching hospital, Kishanganj, Bihar- An Observational Study
Background: Diabetes mellitus and heart failure are two multifaceted entities characterised by high morbidity and mortality. Early epidemiological and prospective studies have observed the frequent coexistence of both co...
Role of MR Enterography (MRE) in Small Bowel Diseases
Introduction: Over recent years there have been significant advances in radiological techniques to better define small bowel lesions. Lack of ionising radiation, superior soft-tissue contrast resolution, capability of dy...